CN110382501A - 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 - Google Patents

用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 Download PDF

Info

Publication number
CN110382501A
CN110382501A CN201780086584.0A CN201780086584A CN110382501A CN 110382501 A CN110382501 A CN 110382501A CN 201780086584 A CN201780086584 A CN 201780086584A CN 110382501 A CN110382501 A CN 110382501A
Authority
CN
China
Prior art keywords
alkyl
aryl
heteroaryl
independently
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780086584.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·梅科嫩
J·A·布特拉
黄建星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenebio Inc
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Priority to CN202310213936.1A priority Critical patent/CN116640143A/zh
Publication of CN110382501A publication Critical patent/CN110382501A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780086584.0A 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法 Pending CN110382501A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310213936.1A CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436272P 2016-12-19 2016-12-19
PCT/IB2017/001762 WO2018130868A1 (en) 2016-12-19 2017-12-20 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310213936.1A Division CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Publications (1)

Publication Number Publication Date
CN110382501A true CN110382501A (zh) 2019-10-25

Family

ID=62557208

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780086584.0A Pending CN110382501A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN202310213936.1A Pending CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310213936.1A Pending CN116640143A (zh) 2016-12-19 2017-12-20 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Country Status (10)

Country Link
US (2) US20180170941A1 (https=)
EP (1) EP3555100B1 (https=)
JP (1) JP7153938B2 (https=)
CN (2) CN110382501A (https=)
AU (1) AU2017393082B2 (https=)
CA (1) CA3047684A1 (https=)
EA (1) EA201991497A1 (https=)
IL (1) IL267451B2 (https=)
MX (1) MX388726B (https=)
WO (2) WO2018130869A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113413532A (zh) * 2021-07-01 2021-09-21 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
CN115175911A (zh) * 2019-12-19 2022-10-11 艾吉因生物股份有限公司 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
MX392119B (es) 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN112601749B (zh) * 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
WO2020072675A1 (en) 2018-10-02 2020-04-09 Northwestern University Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c)
CN116075302A (zh) * 2020-07-10 2023-05-05 艾吉因生物股份有限公司 GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387585A (en) * 1991-06-17 1995-02-07 Hoffmann-La Roche Inc. Imidazodiazepine derivatives
CN1191255C (zh) * 2000-11-16 2005-03-02 弗·哈夫曼-拉罗切有限公司 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN101044145A (zh) * 2004-10-20 2007-09-26 弗·哈夫曼-拉罗切有限公司 咪唑并－苯并二氮杂䓬衍生物
CN103327980A (zh) * 2010-11-15 2013-09-25 艾吉因生物股份有限公司 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法
CN106068256A (zh) * 2013-12-20 2016-11-02 艾吉恩生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
WO2016205739A1 (en) * 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ES413944A1 (es) 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
ES2059602T3 (es) 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
DE69021645T2 (de) 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm And Haas Co., Philadelphia Dihydropyridazinone und Pyridazinone als Fungizide
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
EP0586551A1 (en) 1991-05-24 1994-03-16 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
HK1008417A1 (en) 1994-03-02 1999-05-07 Merck Sharp & Dohme B.V. Sublingual or buccal pharmaceutical composition
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
WO1999025353A1 (en) 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
WO2000027849A2 (en) 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
US6677330B1 (en) 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CZ20032338A3 (cs) 2001-03-01 2004-08-18 Pfizeráproductsáinc Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
AU2002313737A1 (en) 2001-08-13 2003-04-01 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
EP1471909A4 (en) 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20060235021A1 (en) 2002-08-13 2006-10-19 Wesley Blackaby Phenylpyridazine derivatives as ligands for gaba receptors
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
TW200418446A (en) 2002-10-24 2004-10-01 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
NZ540288A (en) 2002-11-22 2009-06-26 Univ Johns Hopkins Target for therapy of cognitive impairment
WO2005079779A1 (en) 2003-10-22 2005-09-01 Merz Pharma Gmbh & Co. Kgaa THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES
WO2006034465A1 (en) 2004-09-23 2006-03-30 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of childhood behavioral disorders
RU2007112675A (ru) 2004-10-12 2008-11-20 Ф.Хоффманн-Ля Рош Аг (Ch) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ
AU2005299031B2 (en) 2004-10-20 2011-11-10 F. Hoffmann-La Roche Ag Halogen substituted benzodiazepine derivatives
EP1828194B1 (en) 2004-12-14 2008-05-28 F. Hoffmann-Roche AG Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US7595395B2 (en) 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
EP2682481A3 (en) 2005-08-03 2014-09-17 The Johns-Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
BRPI0617204A2 (pt) 2005-10-11 2011-07-19 Hoffmann La Roche derivados de imidazo benzodiazepina
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
CA2730148C (en) 2008-08-01 2018-04-03 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
KR20110059652A (ko) 2008-09-24 2011-06-02 이 아이 듀폰 디 네모아 앤드 캄파니 살진균제 피리다진
KR20110066952A (ko) 2008-09-25 2011-06-17 비브 나노, 인코포레이티드 중합체 나노입자 및 활성 성분의 제형을 제조하는 방법
EP2419401A2 (en) 2009-04-17 2012-02-22 XenoPort, Inc. GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
JP2013516497A (ja) 2010-01-11 2013-05-13 ミスリィディオン，インク． 認知増強のための化合物と組成物、製造方法、および治療方法
MX341471B (es) 2010-11-05 2016-08-22 Hoffmann La Roche Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central.
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
JPWO2012161133A1 (ja) 2011-05-20 2014-07-31 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2884566A1 (en) 2012-09-10 2014-03-13 Matthew R. Lewin Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567786A (zh) 2017-03-10 2018-09-25 陈洪国 一种治疗溃疡性结肠炎的药物组合物
CN108567787A (zh) 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
JP7737721B2 (ja) * 2019-12-19 2025-09-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387585A (en) * 1991-06-17 1995-02-07 Hoffmann-La Roche Inc. Imidazodiazepine derivatives
CN1191255C (zh) * 2000-11-16 2005-03-02 弗·哈夫曼-拉罗切有限公司 作为gaba a受体调节剂的苯并二氮杂䓬衍生物
CN101044145A (zh) * 2004-10-20 2007-09-26 弗·哈夫曼-拉罗切有限公司 咪唑并－苯并二氮杂䓬衍生物
CN103327980A (zh) * 2010-11-15 2013-09-25 艾吉因生物股份有限公司 用于治疗认知障碍的苯并二吖庚因衍生物、组合物和方法
CN106068256A (zh) * 2013-12-20 2016-11-02 艾吉恩生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
WO2016205739A1 (en) * 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUIDO ACHERMANN ET AL.: ""Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABAA α5 inverse agonist series", 《BIOORG.MED.CHEM.LETT.》 *
MAX GERECKE ET AL.: "New tetracyclic derivatives of imidazo-[1,5-a][1,4]benzodiazepines and of imidazo-[1,5-a]thieno[3,2-f][1,4]diazepines", 《HETEROCYCLES》 *
MOHD.KAMIL HUSSAIN ET AL.: "Tandem C-2 functionalization-intramolecular azide-alkyne 1,3-dipolar cycloaddtion reaction: A convenient route to highly diversified 9H-benzo[b]pyrrolo[1,2-g][1,2,3]triazolo[1,5-d][1,4]diazepines", 《ORG.LETT》 *
OLIVER JONAS ET AL.: "First in vivo testing of compounds targeting group 3 medulloblastomas using an implantable microdevice as a new paradigm for drug development", 《J BIOMED NANOTECHNOL》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175911A (zh) * 2019-12-19 2022-10-11 艾吉因生物股份有限公司 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
CN116457019A (zh) * 2020-07-10 2023-07-18 艾吉因生物股份有限公司 GABAAα5激动剂的多晶型物及其在治疗认知损害中的使用方法
CN113413532A (zh) * 2021-07-01 2021-09-21 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统
CN113413532B (zh) * 2021-07-01 2022-03-01 曾迎春 基于虚拟现实的癌症相关认知障碍评估与康复训练系统

Also Published As

Publication number Publication date
NZ755287A (en) 2025-06-27
IL267451A (en) 2019-08-29
US20180170941A1 (en) 2018-06-21
WO2018130868A1 (en) 2018-07-19
JP2020512389A (ja) 2020-04-23
IL267451B1 (en) 2023-06-01
EP3555100A4 (en) 2020-06-10
MX388726B (es) 2025-03-20
WO2018130868A8 (en) 2019-08-08
CN116640143A (zh) 2023-08-25
AU2017393082B2 (en) 2022-04-21
JP7153938B2 (ja) 2022-10-17
EA201991497A1 (ru) 2020-01-20
US20230134844A1 (en) 2023-05-04
AU2017393082A1 (en) 2019-07-25
WO2018130869A1 (en) 2018-07-19
IL267451B2 (en) 2023-10-01
MX2019007338A (es) 2019-09-19
EP3555100B1 (en) 2023-05-10
US12528819B2 (en) 2026-01-20
CA3047684A1 (en) 2018-07-19
EP3555100A1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
CN112601749B (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN106068256B (zh) 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CN110382501A (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
CN108026107B (zh) 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40097181A (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
HK40057489A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40049071B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
HK40046882A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40049071A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016541A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254362B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
HK40016046A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230171B (zh) 用於治疗认知损害的苯并二氮杂卓衍生物、组合物和方法
HK1230171A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016541

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20191025

RJ01 Rejection of invention patent application after publication